-
Why Should You Care About Oral Gonorrhea and Oral Human Papillomavirus Infection?
-
Jae Yong Jeong, Seok Cho, Hae Do Jung
-
Urogenit Tract Infect 2023;18(1):20-23. Published online April 30, 2023
-
DOI: https://doi.org/10.14777/uti.2023.18.1.20
-
-
 Abstract
 PDF PubReader ePub
- The incidence of sexually transmitted diseases is increasing with the open-sex culture and as people are having sex at a younger age. Consequently, oral gonorrhea and oral human papillomavirus infections, which are often asymptomatic, result in a high risk of transmission. Oral gonorrhea is symptomatic in less than 20% of patients confirmed by culture for Neisseria gonorrhoeae in both men and women. Even if symptoms develop and oral gonorrhea is diagnosed and treated, the cure rate is less than 90%. Hence, oral gonorrhea can lead to antibiotic resistance to gonorrhea. Oral human papillomavirus infections have received more attention because oral human papillomavirus infections play an important role in the development of oropharyngeal cancer. On the other hand, no test for diagnosing human papillomavirus in the oral cavity has been approved by the US Food and Drug Administration. This lack of test makes it difficult to detect oral human papillomavirus infection early, which can further increase the risk of transmission of human papillomavirus infections. Preventing human papillomavirus infections is very important because surgical resection is the only treatment. Vaccination against human papillomavirus-associated oropharyngeal cancers, including tonsil cancer and base of the tongue cancer, has been reported to be effective in reducing the prevalence of oral human papillomavirus infection in middle-aged adults. Human papillomavirus vaccination is essential for protecting against oral human papillomavirus infection.
-
Gabapentin for the Treatment of Chronic Pelvic Pain Syndrome in Patients with High Pain Score
-
Seok Cho, In-Rae Cho
-
Urogenit Tract Infect 2019;14(2):55-59. Published online August 30, 2019
-
DOI: https://doi.org/10.14777/uti.2019.14.2.55
-
-
Abstract
PDF
- Purpose: The underlying pathogenic mechanisms of chronic pelvic pain syndrome (CPPS) are unclear. A growing body of evidence suggests that the urogenital pain of CPPS may be neuropathic in origin. The objective of this study was to determine if gabapentin can be an effective treatment for the symptoms of CPPS with severe pain.
Materials and Methods: Thirty five males with CPPS (category IIIa 25, IIIb 10) and the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total pain score ≥9 in the previous six months were enrolled in this study between October 2010 and December 2011. The dosage of gabapentin was increased from 300 mg/d to 600 mg/d during the first four weeks. The primary outcome was evaluated as an improvement in the NIH-CPSI from the baseline to week eight.
Results: This study examined 35 males with CPPS and a mean age of 54.2±9.8 years, mean disease duration of 34.2±27.7 months, and a mean prostate volume of 24.9±5.3 ml. The decrease in the total NIH-CPSI pain domain at four weeks was significant with no change observed after eight weeks. Between the category IIIa and IIIb CPPS patients, the change in the total pain domain was not significant.
Conclusions: Gabapentin may be effective in some males with CPPS who have a high pain score. More gabapentin may be useless and possibly harmful if gabapentin does not decrease the pain at four weeks.
|
KAUTI
